EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status

Andrew Dhawan iD, Venkata S K Manem, Gabrielle Yeaney, Justin D Lathia, Manmeet S Ahluwalia

Cancers · 21.01.2023 · 15 (3) · 670

DOI: 10.3390/cancers15030670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 21.01.2023. Verfasst von Andrew Dhawan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma mortality is driven by tumour progression or recurrence despite administering a therapeutic arsenal consisting of surgical resection, radiation, and alkylating chemotherapy. The genetic changes underlying tumour progression and chemotherapy resistance are poorly understood.

Methods

In this study, we sought to define the relationship between EGFR amplification status, EGFR mRNA expression, and EGFR pathway activity. We compared RNA-sequencing data from matched primary and recurrent tumour samples (n = 40 patients, 20 with EGFR amplification).

Results

In the setting of glioblastoma recurrence, the EGFR pathway was overexpressed regardless of EGFR-amplification status, suggesting a common genomic endpoint in recurrent glioblastoma, although EGFR amplification did associate with higher EGFR mRNA expression. Three of forty patients in the study cohort had EGFR-amplified tumours and received targeted EGFR therapy. Their molecular subtypes and clinical outcomes did not significantly differ from patients who received conventional chemotherapy.

Conclusion

Our findings suggest that while the EGFR amplification may confer a unique molecular profile in primary glioblastoma, pathway analysis reveals upregulation of the EGFR pathway in recurrence, regardless of amplification status. As such, the EGFR pathway may be a key mediator of glioblastoma progression.

Schlagwörter

Stichwörter der Autor:innen

EGFRRNA-seqglioblastomarecurrent glioblastomatemozolomide resistance

Autor:innen und Institutionen

  • Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Faculty of Pharmacy, Laval University, Quebec City, QC G1V 0A6, Canada.
  • Department of Mathematics & Computer Science, University of Quebec at Trois-Rivières, Trois-Rivières, QC G8Z 4M3, Canada.
  • Quebec Heart & Lung Institute Research Center, Quebec City, QC G1V 4G5, Canada.
  • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

ORCID-Profile: Andrew Dhawan

Zitieren

APA

Dhawan, A., Manem, V. S. K., Yeaney, G., Lathia, J. D., & Ahluwalia, M. S. (2023). EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers, 15(3), 670. https://doi.org/10.3390/cancers15030670

Vancouver

Dhawan A, Manem VSK, Yeaney G, Lathia JD, Ahluwalia MS. EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status. Cancers. 2023;15(3):670. doi:10.3390/cancers15030670

BibTeX
@article{Dhawan2023,
  author = {Dhawan, Andrew and Manem, Venkata S K and Yeaney, Gabrielle and Lathia, Justin D and Ahluwalia, Manmeet S},
  title = {EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {670},
  doi = {10.3390/cancers15030670}
}
Kostenlos starten →